Sort   by:  
 Page size 
ProteomicsMDM2-amplified esophageal adenocarcinomas exhibit an activated metabolic and immunosuppressive phenotype with multiple potential therapeutic targets
A complete response following neoadjuvant therapy occurs only in a fraction of patients with esophageal adenocarcinoma (EAC). Further targeted treatment options are needed to improve treatment response and patient survival. Mouse double minute 2 homolog (MDM2) is a known oncogene. Its upregulation r...
ORGANISM(S): Homo sapiens (Human) 
2025-12-15 | PXD058762 | Pride
Esophageal adenocarcinomas Tumor microenvironment Met signaling pathway Oncology Proteomics 
ProteomicsProteomic Characterization of SMARCA-Deficient Esophageal Adenocarcinoma Reveals Complement Evasion and DNA Repair-Associated Prognostic Subgroups
Background Esophageal adenocarcinoma (EAC) is an aggressive malignancy in which the SWI/SNF catalytic subunits SMARCA2 and SMARCA4 are frequently lost, yet the biological and clinical impact of these deficiencies remains unclear. Methods We analyzed 113 EAC specimens using mass spectrometry–based pr...
ORGANISM(S): Homo sapiens (Human) 
2026-06-25 | PXD074975 | Pride
Esophageal adenocarcinoma  swi/snf complex  proteomics  smarca2  smarca4  complement system  cd55  cd59  dna repair 
ProteomicsProteomic Characterization of MET-Amplified Esophageal Adenocarcinomas Reveals Enrichment of Alternative Splicing- and Androgen Signaling-Related Proteins
Background Esophageal adenocarcinomas (EACs) represent an evolving tumor entity with high mortality rates. MET amplification is a recurrent driver in EACs and is associated with decreased patient survival. However, the response to MET inhibitors is limited. Recent studies have identified several mec...
ORGANISM(S): Homo sapiens (Human) 
2025-05-07 | PXD059513 | Pride
Esophageal adenocarcinomas Tumor microenvironment Met signaling pathway Oncology Proteomics 
ProteomicsCharacterization of the Angiosarcoma Microenvironment
Angiosarcomas are ultra-rare, highly aggressive sarcomas with limited treatment options and dismal prognosis. In this project, we quantified immune cell infiltrates in the angiosarcoma tumor microenvironment. Unsupervised clustering was applied to reveal prognostically significant immune phenotypes....
ORGANISM(S): Homo sapiens (Human) 
2026-03-13 | PXD070528 | Pride
Sarcoma Angiosarcoma Tumor immune environment Tumor microenvironment 
ProteomicsAdherens junction protein expression is associated with poor response to neoadjuvant FLOT chemotherapy and pro-inflammatory tumor microenvironment in esophageal adenocarcinoma
Esophageal adenocarcinomas represent aggressive gastrointestinal malignancies, characterized by poor survival and variable responses to perioperative therapies. Our study identified a significant association between adherens junction (AJ) protein expression and treatment response to FLOT chemotherap...
ORGANISM(S): Homo sapiens (Human) 
2026-01-06 | PXD071328 | Pride
Esophageal adenocarcinoma Flot perioperative treatment Cell adhesion Tumor microenvironment 
UnknownDLL3 Expression in Neuroendocrine Carcinomas and Neuroendocrine Tumours: Insights From a Multicentric Cohort of 1294 Pulmonary and Extrapulmonary Neuroendocrine Neoplasms.
Not available
S-EPMC11953094 | biostudies-literature
UnknowncIAPs control RIPK1 kinase activity-dependent and -independent cell death and tissue inflammation
Not available
S-SCDT-10_15252-EMBJ_2023113614 | biostudies-other
UnknownPlacental growth factor promotes tumour desmoplasia and treatment resistance in intrahepatic cholangiocarcinoma.
Not available
S-EPMC8666816 | biostudies-literature
UnknownDissecting the genetic heterogeneity of gastric cancer.
Not available
S-EPMC10212786 | biostudies-literature
UnknownCorrigendum to "Dissecting the genetic heterogeneity of gastric cancer".
Not available
S-EPMC10393529 | biostudies-literature
Sort   by:  
 Page size